Phase 3
Completed N=761
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Source: ClinicalTrials.gov NCT00107952 ↗Enrolled (actual)
761
Serious AEs
28.8%
Results posted
Dec 2009
Primary outcomePrimary: Clinical Response — 214; 221; 46; 68 participants
Summary
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Response |
214; 221; 46; 68; 56; 41 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.
Exclusion Criteria
- Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization
Data sourced from ClinicalTrials.gov (NCT00107952). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.